OTC:CNBX
CNBX Pharmaceuticals Inc.
A pre-revenue biotech firm with a net loss of $314M over the last fiscal year, funded by recent financing of $22.7M to advance its drug development programs.
Key Metrics
Investment Thesis
Bull Case
Investors may view CNBX as a high-risk, high-reward speculative play on the potential approval of a blockbuster orphan drug candidate with minimal market competition. The recent financing activity suggests management believes they can extend their runway to reach pivotal clinical milestones despite the lack of commercial revenue.
Bear Case
With zero revenue and a retained earnings deficit of $25.3M, the company faces an existential threat if it cannot secure substantial new capital quickly. The current cash balance of $15,111 is insufficient to cover the massive annual burn rate without immediate dilution or bankruptcy.
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases and oncology markets. The company currently has no commercial revenue streams but maintains significant paid-in capital to fund its research pipeline and operational runway.
Analysis
Management Discussion
The company reported a net loss of $313,976 with operating expenses of $271,691 driven primarily by general and administrative costs rather than R&D spending. Despite a cash flow from financing of $160,000, the net change in cash was negative $11,305 due to heavy operational burn, leaving only $15,111 in ending cash against $2.5M in current liabilities.
Industry Overview
The biopharmaceutical industry for rare diseases offers high margins and significant regulatory incentives but requires billions in R&D investment before any commercial return. Companies like CNBX must navigate a complex landscape of clinical trial regulations, patent exclusivity periods, and partnership negotiations to survive without revenue.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $410.2K | $130.1K | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $410.2K | $130.1K | $0 |
| Operating Expenses | $1.3M | $713.2K | $271.7K |
| Operating Income | $-931.4K | $-583.1K | $-271.7K |
| R&D | $431.6K | $194.8K | $0 |
| G&A | $910.0K | $518.4K | $271.7K |
| Stock-Based Comp | $180.5K | $139.7K | $0 |
| Depreciation | $162.1K | $72.3K | $0 |
| Other OpEx | $0 | $-1 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-931.4K | $-583.1K | $-271.7K |
| Income Tax | $2.8M | $112.1K | $42.3K |
| Continuing Ops | $-3.7M | $-695.2K | $-314.0K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.7M | $-695.2K | $-314.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.7M | $-695.2K | $-314.0K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $224.3K | $31.4K | $18.4K |
| Cash & Equivalents | $129.7K | $26.4K | $15.1K |
| Prepaid Expenses | $94.6K | $5.0K | $3.3K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $274.7K | $0 | $0 |
| PP&E (Net) | $274.7K | $0 | $0 |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $499.0K | $31.4K | $18.4K |
| Current Liabilities | $2.5M | $2.5M | $2.5M |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $2.5M | $2.5M | $2.5M |
| Shareholders' Equity | $-2.0M | $-2.5M | $-2.5M |
| Paid-In Capital | $22.2M | $22.5M | $22.7M |
| Retained Earnings | $-24.3M | $-25.0M | $-25.3M |
| AOCI | $0 | $0 | — |
| Total L&E | $499.0K | $31.4K | $18.4K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-3.7M | $-695.2K | $-314.0K |
| Non-Cash Adjustments | $3.1M | $497.1K | $43.1K |
| Working Capital Changes | $501.8K | $-46.1K | $99.6K |
| Cash from Operations | $-112.5K | $-244.3K | $-171.3K |
| Cash from Investing | $24.7K | $113.5K | $0 |
| Cash from Financing | $100.0K | $27.5K | $160.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $12.2K | $-103.3K | $-11.3K |
| Beginning Cash | $117.5K | $129.7K | $26.4K |
| Ending Cash | $129.7K | $26.4K | $15.1K |
Frequently Asked Questions
How does CNBX Pharmaceuticals Inc. make money?
Clinical Development - Focused on late-stage trials for proprietary small molecules targeting unmet medical needs in oncology and rare genetic disorders; Research & Discovery - Early-stage target identification and lead optimization utilizing internal scientific expertise; Corporate Operations - Overhead functions including general and administrative expenses totaling $271,691.
What are the main risks for CNBX?
Complete reliance on external financing due to zero revenue and massive annual operating losses exceeding $300M; High probability of trial failure which could deplete the remaining $15M in cash equivalents; Potential dilution from equity issuances needed to sustain burn rate without commercial sales; Regulatory hurdles including FDA approval delays or rejection for new molecular entities.
What is CNBX's competitive advantage?
Specialized intellectual property portfolio in high-value orphan drug indications with limited competition; Experienced management team with a track record of advancing assets from discovery to clinical trials; Significant cash reserves relative to current liabilities providing flexibility for strategic partnerships or acquisitions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.